ANI Acquires Alimera Sciences To Bolster Ophthalmology Portfolio
The Move Reflects ANI’s Ambition To Increase Foothold In Rare Disease
Executive Summary
ANI has acquired Alimera Sciences in a move to expand its rare disease business, highlighting its increasing drift from generics.